Search
Skip to Search Results- 4Vaccinia virus
- 2Immunotherapy
- 2Oncolytic virus
- 2Recombination
- 2Ribonucleotide reductase
- 1Bladder cancer
-
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder Cancer
DownloadFall 2017
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
-
Spring 2021
Vaccinia virus (VACV) has shown promise as an oncolytic agent for treating a variety of tumour types, with preliminary results suggesting that this strategy holds promise for treating breast cancer. Our lab has previously modified VACV by deleting virally-encoded enzymes responsible for dNTP...
-
Vaccinia virus DNA polymerase and ribonucleotide reductase: their role in replication, recombination and drug resistance
DownloadSpring 2010
Despite the eradication of smallpox, poxviruses continue to cause human disease around the world. At the core of poxvirus replication is the efficient and accurate synthesis and repair of the viral genome. The viral DNA polymerase is critical for these processes. Acyclic nucleoside phosphonate...
-
Fall 2021
Poxviruses encode many genes that are orthologs of cellular genes. These orthologs serve many functions, but those that are of most interest are ones that have evolved further and now serve an immune-evasion function. Such genes were likely first acquired by poxviruses through some form of...